



(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2020/028900

(22) International Filing Date:
19 April 2020 (19.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/836,247 19 April 2019 (19.04.2019) US
19170438.6 19 April 2019 (19.04.2019) EP

(71) Applicants: **IMMUNOBRAIN CHECKPOINT, INC.**
[US/US]; 3500 S. Dupont Highway, Dover, Delaware
19901 (US). **YEDA RESEARCH AND DEVELOP-
MENT CO. LTD.**, [IL/IL]; Weizmann Institute of Science,
P.O. Box 95, 7610002 Rehovot (IL).

(72) Inventors: **YOLES, Ester**; c/o ImmunoBrain Checkpoint,
Ltd., 3 Pinhas Street, 7414002 Ness Ziona (IL). **KROGH,
Berit Olsen**; c/o H. Lundbeck A/S, Ottiliavej 9, 2500 Val-
by (DK). **JENSEN, Allan**; c/o H. Lundbeck A/S, Ottili-
avej 9, 2500 Valby (DK). **EGEBJERG, Jan**; c/o H. Lund-
beck A/S, Ottiliavej 9, 2500 Valby (DK). **DAVID, Car-
ol**; c/o ImmunoBrain Checkpoint, Ltd., 3 Pinhas Street,
7414002 Ness Ziona (IL). **BARUCH, Kuti**; c/o Immuno-
Brain Checkpoint, Ltd., 3 Pinhas Street, 7414002 Ness
Ziona (IL). **EISENBACH-SCHWARTZ, Michal**; c/o Im-
munoBrain Checkpoint, Ltd., 3 Pinhas Street, 7414002 Ness
Ziona (IL).

(74) Agent: **STATHAKIS, Dean**; UltimatEdge IP Law Group,
P.C., 2372 Morse Avenue, Suite 252, Irvine, California
92614-6234 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: MODIFIED ANTI-PD-L1 ANTIBODIES AND METHODS AND USES FOR TREATING A NEURODEGENERATIVE DISEASE





FIG. 32



(57) Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*